Alnylam Pharmaceuticals’ (ALNY) Buy Rating Reiterated at B. Riley

B. Riley restated their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research note released on Monday, MarketBeat reports. B. Riley currently has a $205.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $220.00. B. Riley also issued estimates for Alnylam Pharmaceuticals’ Q4 2017 earnings at ($1.60) EPS, FY2017 earnings at ($5.32) EPS, Q2 2018 earnings at ($1.46) EPS, Q3 2018 earnings at ($1.14) EPS, Q4 2018 earnings at ($1.20) EPS and FY2018 earnings at ($4.90) EPS.

ALNY has been the subject of a number of other research reports. JMP Securities lifted their price objective on Alnylam Pharmaceuticals from $101.00 to $128.00 and gave the company an outperform rating in a research report on Wednesday, September 20th. Barclays lifted their price objective on Alnylam Pharmaceuticals from $127.00 to $158.00 and gave the company an overweight rating in a research report on Wednesday, November 8th. FBR & Co assumed coverage on Alnylam Pharmaceuticals in a research report on Monday, October 30th. They issued a buy rating and a $150.00 price objective for the company. Cowen reaffirmed an outperform rating and issued a $151.00 price objective (up previously from $117.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, November 3rd. Finally, Needham & Company LLC reaffirmed a buy rating and issued a $152.00 price objective (up previously from $125.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, November 3rd. Three research analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. The company has an average rating of Buy and a consensus target price of $121.20.

Alnylam Pharmaceuticals (NASDAQ ALNY) opened at $128.60 on Monday. The company has a current ratio of 9.83, a quick ratio of 9.83 and a debt-to-equity ratio of 0.14. The firm has a market capitalization of $12,650.00, a price-to-earnings ratio of -24.50 and a beta of 2.98. Alnylam Pharmaceuticals has a 1 year low of $35.98 and a 1 year high of $147.63.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.11). The company had revenue of $17.10 million for the quarter, compared to analysts’ expectations of $28.15 million. Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The business’s quarterly revenue was up 24.8% on a year-over-year basis. During the same period in the previous year, the business posted ($1.21) EPS. sell-side analysts forecast that Alnylam Pharmaceuticals will post -5.21 EPS for the current fiscal year.

In other Alnylam Pharmaceuticals news, SVP Laurie Keating sold 6,249 shares of the business’s stock in a transaction dated Wednesday, December 20th. The stock was sold at an average price of $121.20, for a total transaction of $757,378.80. Following the transaction, the senior vice president now owns 17,749 shares in the company, valued at $2,151,178.80. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Michael Mason sold 36,745 shares of the business’s stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $131.59, for a total value of $4,835,274.55. Following the transaction, the vice president now owns 6,352 shares in the company, valued at approximately $835,859.68. The disclosure for this sale can be found here. Insiders sold 274,075 shares of company stock worth $35,356,089 in the last quarter. 4.30% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently modified their holdings of ALNY. Schwab Charles Investment Management Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 33.4% during the second quarter. Schwab Charles Investment Management Inc. now owns 243,415 shares of the biopharmaceutical company’s stock worth $19,415,000 after purchasing an additional 60,906 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Alnylam Pharmaceuticals by 9.2% during the second quarter. Bank of New York Mellon Corp now owns 333,942 shares of the biopharmaceutical company’s stock worth $26,634,000 after purchasing an additional 28,260 shares in the last quarter. Legal & General Group Plc lifted its stake in shares of Alnylam Pharmaceuticals by 12.7% during the second quarter. Legal & General Group Plc now owns 27,883 shares of the biopharmaceutical company’s stock worth $2,224,000 after purchasing an additional 3,144 shares in the last quarter. Prudential Financial Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 4.8% during the second quarter. Prudential Financial Inc. now owns 4,404 shares of the biopharmaceutical company’s stock worth $351,000 after purchasing an additional 200 shares in the last quarter. Finally, Neuberger Berman Group LLC acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth about $229,000. Institutional investors own 88.39% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.themarketsdaily.com/2018/01/11/alnylam-pharmaceuticals-alny-buy-rating-reiterated-at-b-riley.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply